Ingo Janssen1,2, Clara C Chen3, Corina M Millo4, Alexander Ling5, David Taieb6, Frank I Lin7, Karen T Adams1, Katherine I Wolf1, Peter Herscovitch4, Antonio T Fojo8, Inga Buchmann2, Electron Kebebew9, Karel Pacak10. 1. Program in Adult and Reproductive Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Building 10, CRC, Room 1E-3140, 10 Center Drive MSC-1109, Bethesda, MD, 20892, USA. 2. Department of Radiology and Nuclear Medicine, Section of Nuclear Medicine, University Hospital Schleswig Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany. 3. Nuclear Medicine Division, Radiology & Imaging Sciences, National Institutes of Health Clinical Center, Bethesda, MD, 20892, USA. 4. Positron Emission Tomography Department, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD, 20892, USA. 5. Radiology and Imaging Sciences, National Institutes of Health Clinical Center, Bethesda, MD, 20892, USA. 6. Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, Marseille, France. 7. Cancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA. 8. Endocrine Oncology Branch, National Cancer Institute, Bethesda, MD, 20892, USA. 9. Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, USA. 10. Program in Adult and Reproductive Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Building 10, CRC, Room 1E-3140, 10 Center Drive MSC-1109, Bethesda, MD, 20892, USA. karel@mail.nih.gov.
Abstract
PURPOSE: Pheochromocytomas/paragangliomas (PPGLs) and their metastases are tumors that predominantly express somatostatin receptor 2 (SSR2). (68)Ga-DOTA(0)-Tyr(3)-octreotate ((68)Ga-DOTATATE) is a PET radiopharmaceutical with both high and selective affinity for SSRs. The purpose of this study was to evaluate the utility of (68)Ga-DOTATATE in comparison with other specific and nonspecific radiopharmaceuticals recommended in the current guidelines for the localization of metastatic sporadic PPGL by PET/CT. METHODS: This prospective study included 22 patients (15 men, 7 women; aged 50.0 ± 13.9 years) with confirmed metastatic PPGL, a negative family history for PPGL, and negative genetic testing, who underwent (68)Ga-DOTATATE, (18)F-fluoro-2-deoxy-D-glucose ((18)F-FDG) PET/CT, and CT/MRI. Only 12 patients underwent an additional (18)F-fluorodihydroxyphenylalanine ((18)F-FDOPA) PET/CT scan and only 11 patients underwent an additional (18)F-fluorodopamine ((18)F-FDA) PET/CT scan. The rates of detection of metastatic lesions were compared among all the imaging studies. A composite of all functional and anatomical imaging studies served as the imaging comparator. RESULTS: (68)Ga-DOTATATE PET/CT showed a lesion-based detection rate of 97.6 % (95 % confidence interval, CI, 95.8 - 98.7 %). (18)F-FDG PET/CT, (18)F-FDOPA PET/CT, (18)F-FDA PET/CT, and CT/MRI showed detection rates of 49.2 % (CI 44.5 - 53.6 %; p < 0.01), 74.8 % (CI 69.0 - 79.9 %); p < 0.01), 77.7 % (CI 71.5 - 82.8 %; p < 0.01), and 81.6 % (CI 77.8 - 84.8 %; p < 0.01), respectively. CONCLUSION: The results of this study demonstrate the superiority of (68)Ga-DOTATATE PET/CT in the localization of sporadic metastatic PPGLs compared to all other functional and anatomical imaging modalities, and suggest modification of future guidelines towards this new imaging modality.
PURPOSE:Pheochromocytomas/paragangliomas (PPGLs) and their metastases are tumors that predominantly express somatostatin receptor 2 (SSR2). (68)Ga-DOTA(0)-Tyr(3)-octreotate ((68)Ga-DOTATATE) is a PET radiopharmaceutical with both high and selective affinity for SSRs. The purpose of this study was to evaluate the utility of (68)Ga-DOTATATE in comparison with other specific and nonspecific radiopharmaceuticals recommended in the current guidelines for the localization of metastatic sporadic PPGL by PET/CT. METHODS: This prospective study included 22 patients (15 men, 7 women; aged 50.0 ± 13.9 years) with confirmed metastatic PPGL, a negative family history for PPGL, and negative genetic testing, who underwent (68)Ga-DOTATATE, (18)F-fluoro-2-deoxy-D-glucose ((18)F-FDG) PET/CT, and CT/MRI. Only 12 patients underwent an additional (18)F-fluorodihydroxyphenylalanine ((18)F-FDOPA) PET/CT scan and only 11 patients underwent an additional (18)F-fluorodopamine ((18)F-FDA) PET/CT scan. The rates of detection of metastatic lesions were compared among all the imaging studies. A composite of all functional and anatomical imaging studies served as the imaging comparator. RESULTS: (68)Ga-DOTATATE PET/CT showed a lesion-based detection rate of 97.6 % (95 % confidence interval, CI, 95.8 - 98.7 %). (18)F-FDG PET/CT, (18)F-FDOPA PET/CT, (18)F-FDA PET/CT, and CT/MRI showed detection rates of 49.2 % (CI 44.5 - 53.6 %; p < 0.01), 74.8 % (CI 69.0 - 79.9 %); p < 0.01), 77.7 % (CI 71.5 - 82.8 %; p < 0.01), and 81.6 % (CI 77.8 - 84.8 %; p < 0.01), respectively. CONCLUSION: The results of this study demonstrate the superiority of (68)Ga-DOTATATE PET/CT in the localization of sporadic metastatic PPGLs compared to all other functional and anatomical imaging modalities, and suggest modification of future guidelines towards this new imaging modality.
Authors: A Kroiss; D Putzer; C Decristoforo; C Uprimny; B Warwitz; B Nilica; M Gabriel; D Kendler; D Waitz; G Widmann; I J Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2013-01-05 Impact factor: 9.236
Authors: Henri J L M Timmers; Clara C Chen; Jorge A Carrasquillo; Millie Whatley; Alexander Ling; Graeme Eisenhofer; Kathryn S King; Jyotsna U Rao; Robert A Wesley; Karen T Adams; Karel Pacak Journal: J Natl Cancer Inst Date: 2012-04-18 Impact factor: 13.506
Authors: Samira M Sadowski; Corina Millo; Candice Cottle-Delisle; Roxanne Merkel; Lily A Yang; Peter Herscovitch; Karel Pacak; William F Simonds; Stephen J Marx; Electron Kebebew Journal: J Am Coll Surg Date: 2015-04-20 Impact factor: 6.113
Authors: Henri J L M Timmers; Mohiuddin Hadi; Jorge A Carrasquillo; Clara C Chen; Lucia Martiniova; Millie Whatley; Alexander Ling; Graeme Eisenhofer; Karen T Adams; Karel Pacak Journal: J Nucl Med Date: 2007-09-14 Impact factor: 10.057
Authors: Bas Havekes; Kathryn King; Edwin W Lai; Johannes A Romijn; Eleonora P M Corssmit; Karel Pacak Journal: Clin Endocrinol (Oxf) Date: 2009-06-08 Impact factor: 3.478
Authors: Chenue Abongwa; Sarah Mott; Blanca Schafer; Parren McNeely; Ghada Abusin; Thomas O'Dorisio; Gideon Zamba; M Sue O'Dorisio; Yusuf Menda Journal: Am J Nucl Med Mol Imaging Date: 2017-11-01
Authors: Arthur Varoquaux; Electron Kebebew; Fréderic Sebag; Katherine Wolf; Jean-François Henry; Karel Pacak; David Taïeb Journal: Endocr Relat Cancer Date: 2016-07-12 Impact factor: 5.678
Authors: Abhishek Jha; Alexander Ling; Corina Millo; Garima Gupta; Bruna Viana; Frank I Lin; Peter Herscovitch; Karen T Adams; David Taïeb; Adam R Metwalli; W Marston Linehan; Alessandra Brofferio; Constantine A Stratakis; Electron Kebebew; Maya Lodish; Ali Cahid Civelek; Karel Pacak Journal: Eur J Nucl Med Mol Imaging Date: 2017-12-04 Impact factor: 9.236